ClinicalTrials.gg
CompletedNCT02706847SELECT-BEYONDUpdated Feb 8, 2023Results posted

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs

A Phase 3 interventional study of Placebo and Upadacitinib in Rheumatoid Arthritis, sponsored by AbbVie. Completed at 188 sites in 27 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
499
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing upadacitinib in Arthritis, Rheumatoid — 3 open to participants now, 3 under way, none of them phase 3. upadacitinib · Arthritis, Rheumatoid.

Enrollment
5th of 19
499 · median 300
Started
2016
with 3 others
Phase 3
7 of 19
none open now
Registered
6th of 19
by date
Lead sponsor
13 of 19
AbbVie

Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, this one is the 5th largest by enrollment, is one of 4 that started in 2016, is one of 7 in phase 3, and was the 6th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 19 studies testing upadacitinib in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing upadacitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The study objective of Period 1 (Day 1 to Week 24) is to compare the safety and efficacy of upadacitinib 30 mg once daily (QD) and 15 mg QD versus placebo for the treatment of signs and symptoms of participants with moderately to severely active rheumatoid arthritis (RA) who are on a stable dose of csDMARDs and had an inadequate response to or intolerance to at least 1 bDMARD.

The study objective of Period 2 (Week 24 to Week 260) is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD and 30 mg QD in participants with RA who completed Period 1.

Read the detailed description

This study includes a 35-day screening period; a 24-week randomized, double-blind, parallel-group, placebo controlled treatment period (Period 1); a 236-week blinded long-term extension period (Period 2); and a 30-day follow-up period (call or visit).

Period 1 consists of a 12-week double-blind, placebo-controlled treatment phase plus a 12-week double-blind phase where all participants were to receive upadacitinib; at Week 12 participants assigned to placebo will be switched to upadacitinib according to their randomization assignment.

Participants who meet eligibility criteria will be randomized in a 2:2:1:1 ratio to one of four treatment groups:

  • Group 1: Upadacitinib 30 mg QD (Day 1 to Week 12) → upadacitinib 30 mg QD (Week 12 and thereafter)
  • Group 2: Upadacitinib 15 mg QD (Day 1 to Week 12) → upadacitinib 15 mg QD (Week 12 and thereafter)
  • Group 3: Placebo (Day 1 to Week 12) → upadacitinib 30 mg QD (Week 12 and thereafter)
  • Group 4: Placebo (Day 1 to Week 12) → upadacitinib 15 mg QD (Week 12 and thereafter)

Participants will continue stable dose of csDMARD therapy for the first 24 weeks of the study.

Participants who complete the Week 24 visit (end of Period 1) will enter the blinded long-term extension portion of the study, Period 2 and continue to receive the same dose of upadacitinib per original randomization assignment in a blinded manner. Starting at Week 24, at least 20% improvement in both swollen joint count (SJC) and tender joint count (TJC) compared to Baseline is required to remain on study drug. Starting at Week 24, initiation of or change in corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or adding or increasing doses in up to 2 csDMARDs (concomitant use of up to 2 csDMARDs except the combination of methotrexate and leflunomide) is allowed as per local label.

With the implementation of Protocol Amendment 4, all participants in the extension period will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 mg QD.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Musculoskeletal Disease
  • Arthritis
  • Joint Disease
  • Anti-inflammatory agents
  • Antirheumatic agents
  • ABT-494
  • upadacitinib
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of rheumatoid arthritis (RA) for≥ 3 months.
  • Treated for ≥ 3 months with ≥ 1 bDMARD therapy, but continue to exhibit active RA or had to discontinue due to intolerability or toxicity, irrespective of treatment duration prior to the first dose of study drug.
  • Participant has been receiving csDMARD therapy ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug. The following csDMARDs are allowed: methotrexate (MTX), sulfasalazine, hydroxychloroquine, chloroquine, and leflunomide. A combination of up to two background csDMARDs is allowed except the combination of MTX and leflunomide.
  • Meets both of the following criteria:
  • ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits.
  • hsCRP ≥ 3mg/L at Screening Visit.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib).
  • History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than RA (including but not limited to gout, systemic lupus erythematosus, psoriatic arthritis, axial spondyloarthritis including ankylosing spondylitis and non-radiographic axial spondyloarthritis, reactive arthritis, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia [currently with active symptoms]). Current diagnosis of secondary Sjogren's Syndrome is permitted.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
499 participants (actual)

Study arms

  • Experimental
    Upadacitinib 15 mg

    Period 1: Participants receive upadacitinib 15 mg once daily for 24 weeks. Period 2: Participants will continue on upadacitinib 15 mg once daily from Week 24 to Week 260.

    Drug: Upadacitinib

  • Experimental
    Upadacitinib 30 mg

    Period 1: Participants receive upadacitinib 30 mg once daily for 24 weeks. Period 2: Participants continue on upadacitinib 30 mg once daily until implementation of Protocol Amendment 4, then participants begin to receive upadacitinib 15 mg once daily up to Week 260.

    Drug: Upadacitinib

  • Placebo comparator
    Placebo / Upadacitnib 15 mg

    Period 1: Participants receive placebo once daily for 12 weeks followed by upadacitinib 15 mg once daily for 12 weeks. Period 2: Participants will continue on upadacitinib 15 mg once daily from Week 24 to Week 260.

    Drug: Placebo · Drug: Upadacitinib

  • Placebo comparator
    Placebo / Upadacitnib 30 mg

    Period 1: Participants receive placebo once daily for 12 weeks followed by upadacitinib 30 mg once daily for 12 weeks. Period 2: Participants continue on upadacitinib 30 mg once daily until implementation of Protocol Amendment 4, then participants begin to receive upadacitinib 15 mg once daily up to Week 260.

    Drug: Placebo · Drug: Upadacitinib

Interventions

  • DrugPlacebo

    Tablet; Oral

  • Tablet; Oral

    Also known as: ABT-494, RINVOQ®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12

    The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 12. Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

  2. Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12

    The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was low disease activity, based on a Disease Activity Score 28 (DAS28)-CRP score of ≤ 3.2 at Week 12. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28 score less than or equal to 3.2 indicates low disease activity.

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline in in Disease Activity Score 28 (CRP) at Week 12

    The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline in DAS28 (CRP) indicates improvement in disease activity.

    Time frame: Baseline and Week 12

  2. Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

    Time frame: Baseline and Week 12

  3. Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12

    The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.

    Time frame: Baseline and Week 12

  4. Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

  5. Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

  6. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and week 1

07

Results

Posted Oct 7, 2019

Participant flow

Participants were enrolled at 152 sites located in 26 countries from March 2016 to January 2017. Eligible participants had active rheumatoid arthritis (RA) and previous inadequate response or intolerance to biologic disease-modifying anti-rheumatic drugs (bDMARDs), and were receiving concomitant background conventional synthetic DMARDS (csDMARDs).

Period 1: Day 1 to Week 12
Participant flow — Period 1: Day 1 to Week 12
MilestonePlacebo / Upadacitinib 15 mgPlacebo / Upadacitinib 30 mgUpadacitinib 15 mgUpadacitinib 30 mg
Started8584165165
Received study treatment8584164165
Completed7576157149
Not completed108816
Withdrew: Adverse event22112
Withdrew: Withdrawal by subject2142
Withdrew: Lost to follow-up2100
Withdrew: Other4422
Withdrew: Randomized in error0010
Period 1: Week 12 to Week 24
Participant flow — Period 1: Week 12 to Week 24
MilestonePlacebo / Upadacitinib 15 mgPlacebo / Upadacitinib 30 mgUpadacitinib 15 mgUpadacitinib 30 mg
Started7576157149
Received study treatment7275156148
Completed7274153135
Not completed32414
Withdrew: Adverse event1225
Withdrew: Withdrawal by subject1014
Withdrew: Lost to follow-up0001
Withdrew: Other1014
Period 2: Week 24 to Week 260
Participant flow — Period 2: Week 24 to Week 260
MilestonePlacebo / Upadacitinib 15 mgPlacebo / Upadacitinib 30 mgUpadacitinib 15 mgUpadacitinib 30 mg
Started7173152132
Switched to upadacitinib 15 mg after protocol amendment 4044094
Completed35418182
Not completed36327150
Withdrew: Adverse event1192111
Withdrew: Withdrawal by subject11101710
Withdrew: Lost to follow-up1596
Withdrew: Lack of efficacy5398
Withdrew: Other851515

Outcome measures

PrimaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12

The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 12. Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
percentage of participantsPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1228.4 (21.6 to 35.2)64.6 (57.3 to 72.0)56.4 (48.8 to 63.9)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Response rate difference: 36.2 · 95% CI 26.2 to 46.2Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Response rate difference: 28.0 · 95% CI 17.8 to 38.1Response Rate Difference = Upadacitinib - Placebo
PrimaryPercentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12

The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was low disease activity, based on a Disease Activity Score 28 (DAS28)-CRP score of ≤ 3.2 at Week 12. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28 score less than or equal to 3.2 indicates low disease activity.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12
percentage of participantsPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 1214.2 (8.9 to 19.5)43.3 (35.7 to 50.9)42.4 (34.9 to 50.0)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Response rate difference: 29.1 · 95% CI 19.9 to 38.3Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Response rate difference: 28.2 · 95% CI 19.0 to 37.4Response Rate Difference = Upadacitinib - Placebo
SecondaryChange From Baseline in in Disease Activity Score 28 (CRP) at Week 12

The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline in DAS28 (CRP) indicates improvement in disease activity.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in in Disease Activity Score 28 (CRP) at Week 12
units on a scalePlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in in Disease Activity Score 28 (CRP) at Week 12-1.02 (-1.23 to -0.80)-2.31 (-2.52 to -2.10)-2.29 (-2.50 to -2.09)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · ANCOVA · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: -1.29 · 95% CI -1.57 to -1.01Treatment Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · ANCOVA · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: -1.28 · 95% CI -1.56 to -0.99Treatment Difference = Upadacitinib - Placebo
SecondaryChange From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12
units on a scalePlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12-0.17 (-0.26 to -0.08)-0.39 (-0.48 to -0.30)-0.42 (-0.51 to -0.33)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · ANCOVA · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: -0.22 · 95% CI -0.34 to -0.10Treatment Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · ANCOVA · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: -0.25 · 95% CI -0.38 to -0.13Treatment Difference = Upadacitinib - Placebo
SecondaryChange From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12

The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12
units on a scalePlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 122.39 (1.14 to 3.64)5.83 (4.60 to 7.05)7.02 (5.78 to 8.25)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Mixed Effect Model Repeat Measurement · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: 3.44 · 95% CI 1.72 to 5.15Treatment Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Mixed Effect Model Repeat Measurement · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: 4.63 · 95% CI 2.89 to 6.36Treatment Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12

Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
percentage of participantsPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 1211.8 (7.0 to 16.7)34.1 (26.9 to 41.4)35.8 (28.4 to 43.1)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The nominal p-value is reported) · Response rate difference: 22.3 · 95% CI 13.6 to 31.1Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The nominal p-value is reported) · Response rate difference: 23.9 · 95% CI 15.1 to 32.7Response Rate Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12

Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12
percentage of participantsPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 126.5 (2.8 to 10.2)11.6 (6.7 to 16.5)23.0 (16.6 to 29.5)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = 0.110 (The nominal p-value is reported) · Response rate difference: 5.1 · 95% CI -1.1 to 11.2Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The nominal p-value is reported) · Response rate difference: 16.5 · 95% CI 9.1 to 23.9Response Rate Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1

Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and week 1
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1
percentage of participantsPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 110.7 (6.0 to 15.3)27.4 (20.6 to 34.3)24.8 (18.3 to 31.4)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The nominal p-value is reported) · Response rate difference: 16.8 · 95% CI 8.5 to 25.1Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The nominal p-value is reported) · Response rate difference: 14.2 · 95% CI 6.1 to 22.3Response Rate Difference = Upadacitinib - Placebo

Adverse events

Collected over Adverse events are reported for Weeks 1 to 12 (all participants) and from Weeks 1 to 260 for participants who received upadacitinib.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo: Weeks 1-120/169 (0%)0/169 (0%)68/169 (40.2%)
Upadacitinib 15 mg: Weeks 1-120/164 (0%)9/164 (5.5%)68/164 (41.5%)
Upadacitinib 30 mg: Weeks 1-121/165 (0.6%)12/165 (7.3%)78/165 (47.3%)
Upadacitinib 15 mg: Weeks 1-2609/236 (3.8%)87/236 (36.9%)196/236 (83.1%)
Upadacitinib 30 mg: Weeks 1-260/Switch5/240 (2.1%)71/240 (29.6%)203/240 (84.6%)
Upadacitinib 15 mg After Switch2/138 (1.4%)21/138 (15.2%)59/138 (42.8%)
Most frequent serious events
Showing 10 of 202
Most frequent serious events
EventPlacebo: Weeks 1-12Upadacitinib 15 mg: Weeks 1-12Upadacitinib 30 mg: Weeks 1-12Upadacitinib 15 mg: Weeks 1-260Upadacitinib 30 mg: Weeks 1-260/SwitchUpadacitinib 15 mg After Switch
PneumoniaInfections and infestations0/1690/1642/1655/2369/2401/138
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1691/1641/1657/2363/2401/138
OsteoarthritisMusculoskeletal and connective tissue disorders0/1691/1640/1655/2367/2402/138
Deep vein thrombosisVascular disorders0/1690/1640/1655/2361/2401/138
Acute myocardial infarctionCardiac disorders0/1690/1640/1654/2361/2400/138
COVID-19Infections and infestations0/1690/1640/1654/2361/2402/138
COVID-19 pneumoniaInfections and infestations0/1690/1640/1653/2360/2402/138
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/1690/1640/1652/2360/2402/138
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/1691/1640/1653/2360/2400/138
VomitingGastrointestinal disorders0/1690/1640/1650/2363/2400/138
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPlacebo: Weeks 1-12Upadacitinib 15 mg: Weeks 1-12Upadacitinib 30 mg: Weeks 1-12Upadacitinib 15 mg: Weeks 1-260Upadacitinib 30 mg: Weeks 1-260/SwitchUpadacitinib 15 mg After Switch
Upper respiratory tract infectionInfections and infestations13/16913/16411/16574/23667/2401/138
Urinary tract infectionInfections and infestations10/16916/1649/16543/23649/24011/138
NasopharyngitisInfections and infestations11/1697/1649/16534/23641/2403/138
Rheumatoid arthritisMusculoskeletal and connective tissue disorders10/1694/1646/16534/23639/24013/138
BronchitisInfections and infestations4/1697/1644/16527/23637/2400/138
Herpes zosterInfections and infestations1/1692/1642/16522/23632/2408/138
HypertensionVascular disorders4/1693/1643/16529/23619/2403/138
CoughRespiratory, thoracic and mediastinal disorders2/1694/1643/16528/23619/2403/138
ArthralgiaMusculoskeletal and connective tissue disorders5/1691/1642/16526/23628/2404/138
Blood creatine phosphokinase increasedInvestigations0/1692/1643/16518/23627/2404/138

Baseline characteristics

The full analysis set (FAS) included all randomized participants who received at least 1 dose of study drug. The 2 placebo groups were combined for analysis of data through Week 12.

Age, Continuous
Age, Continuous(years)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
Mean57.6 ± 11.3956.3 ± 11.3457.3 ± 11.5557.1 ± 11.42
Age, Customized
Age, Customized(Participants)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
< 40 years14111439
40 - 64 years106115103324
≥ 65 years493848135
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
Female143137138418
Male26272780
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
Hispanic or Latino24342886
Not Hispanic or Latino145130137412
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
White143142148433
Black or African American21171048
American Indian/Alaska Native0347
Native Hawaiian or other Pacific Islander0011
Asian5229
Geographic Region
Geographic Region(Participants)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
North America110109109328
Western Europe33323297
Eastern Europe23222267
Asia0011
Other3115
Prior Failed Biological Disease-modifying Anti-rheumatic Drugs (bDMARDs)
Prior Failed Biological Disease-modifying Anti-rheumatic Drugs (bDMARDs)(Participants)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
Stratum 1117116111344
Stratum 2524854154
Duration of RA Diagnosis
Duration of RA Diagnosis(years)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
Mean14.5 ± 9.2212.4 ± 9.3812.7 ± 9.6513.2 ± 9.45

9 further baseline measures are reported on the registry.

08

Study locations

188 sites
  • Rheum Assoc of North Alabama /ID# 145959
    Huntsville, Alabama 35801, United States
  • AZ Arthritis and Rheum Assoc /ID# 148593
    Mesa, Arizona 85202, United States
  • AZ Arthritis and Rheum Researc /ID# 142816
    Phoenix, Arizona 85032-9306, United States
  • AZ Arthritis and Rheum Researc /ID# 146075
    Phoenix, Arizona 85032-9306, United States
  • AZ Arthritis and Rheum Researc /ID# 148592
    Phoenix, Arizona 85032-9306, United States
  • Arizona Research Center, Inc. /ID# 142741
    Phoenix, Arizona 85053-4061, United States
  • AZ Arthr & Rheum Research /ID# 155256
    Prescott, Arizona 86305, United States
  • AZ Arthritis & Rheum Research /ID# 156090
    Sun City, Arizona 85351, United States
  • NEA Baptist Clinic /ID# 149280
    Jonesboro, Arkansas 72401, United States
  • Covina Arthritis Clinic /ID# 142794
    Covina, California 91722, United States
  • Rheumatology Ctr of San Diego /ID# 153576
    Escondido, California 92025, United States
  • St. Joseph Heritage Healthcare /ID# 149273
    Fullerton, California 92835, United States
  • TriWest Research Associates- La Mesa /ID# 142792
    La Mesa, California 91942, United States
  • Arthritis & Osteo Medical Ctr /ID# 142770
    La Palma, California 90623-1728, United States
  • Valerius Med Grp & Res Ctr /ID# 142799
    Los Alamitos, California 90720-5402, United States
  • Pacific Arthritis Ctr Med Grp /ID# 142783
    Los Angeles, California 90045, United States
  • University of California, Los Angeles /ID# 148348
    Los Angeles, California 90095, United States
  • Desert Medical Advances /ID# 142765
    Palm Desert, California 92260, United States
  • Stanford University School of Med /ID# 142761
    Stanford, California 94305-2200, United States
  • Robin K. Dore MD, Inc /ID# 150908
    Tustin, California 92780, United States
  • Inland Rheum Clin Trials Inc. /ID# 142787
    Upland, California 91786, United States
  • Medvin Clinical Research /ID# 142814
    Whittier, California 90606, United States
  • Arthritis Assoc & Osteo Ctr /ID# 142809
    Colorado Springs, Colorado 80920, United States
  • Denver Arthritis Clinic /ID# 142771
    Denver, Colorado 80230, United States
  • New England Research Associates, LLC /ID# 142763
    Bridgeport, Connecticut 06606-1827, United States
  • Delaware Arthritis /ID# 142803
    Lewes, Delaware 19958, United States
  • Lakes Research, LLC /ID# 142755
    Miami, Florida 33014, United States
  • Medallion Clinical Research Institute, LLC /ID# 142740
    Naples, Florida 34102, United States
  • Omega Research Consultants /ID# 142780
    Orlando, Florida 32810, United States
  • Millennium Research /ID# 142782
    Ormond Beach, Florida 32174, United States
  • Arthritis Research of Florida /ID# 142811
    Palm Harbor, Florida 34684-2672, United States
  • Arthritis Center, Inc. /ID# 142822
    Palm Harbor, Florida 34684, United States
  • Advent Clinical Research /ID# 142817
    Pinellas Park, Florida 33781, United States
  • St. Anthony Comprehsve Res Ins /ID# 148349
    Saint Petersburg, Florida 33705, United States
  • University of South Florida /ID# 145611
    Tampa, Florida 33612, United States
  • BayCare Medical Group, Inc. /ID# 142747
    Tampa, Florida 33614-7101, United States
  • Lovelace Scientific Resources /ID# 142779
    Venice, Florida 34292, United States
  • Jefrey D. Lieberman, MD, P.C. /ID# 151713
    Decatur, Georgia 30033, United States
  • Marietta Rheumatology Assoc /ID# 151347
    Marietta, Georgia 30060, United States
  • St. Luke's Clinic - Rheumatolo /ID# 150923
    Boise, Idaho 83702, United States
  • Institute of Arthritis Res /ID# 142810
    Idaho Falls, Idaho 83404, United States
  • Advanced Clinical Research /ID# 153089
    Meridian, Idaho 83642, United States
  • Great Lakes Clinical Trials /ID# 148341
    Chicago, Illinois 60640, United States
  • Clinical Investigation Special /ID# 149270
    Skokie, Illinois 60076, United States
  • Springfield Clinic /ID# 142818
    Springfield, Illinois 62702-3749, United States
  • Deerbrook Medical Associates /ID# 151712
    Vernon Hills, Illinois 60061, United States
  • The Arthritis & Diabetes Clinic, Inc. /ID# 142793
    Monroe, Louisiana 71203, United States
  • Vanguard Medical Research, LLC /ID# 153123
    Shreveport, Louisiana 71011, United States
  • MMP Women's Health /ID# 145612
    Portland, Maine 04102, United States
  • The Center for Rheumatology & /ID# 142742
    Wheaton, Maryland 20902, United States
  • Mansfield Health Center /ID# 147628
    Mansfield, Massachusetts 02048, United States
  • Clinical Pharmacology Study Gr /ID# 142744
    Worcester, Massachusetts 01605, United States
  • June DO, PC /ID# 142756
    Lansing, Michigan 48910, United States
  • North Mississippi Med Clinics /ID# 142781
    Tupelo, Mississippi 38801, United States
  • Clayton Medical Associates dba Saint Louis Rheumatology /ID# 142745
    Saint Louis, Missouri 63119-3845, United States
  • Barbara Caciolo, MD /ID# 142749
    Saint Louis, Missouri 63139-2338, United States
  • Westroads Clinical Research /ID# 142802
    Omaha, Nebraska 68114, United States
  • Dartmouth-Hitchcock Medical Center /ID# 145958
    Lebanon, New Hampshire 03756, United States
  • Atlantic Coast Research /ID# 148347
    Toms River, New Jersey 08755, United States
  • Ocean Rheumatology, PA /ID# 142785
    Toms River, New Jersey 08755, United States
  • The Center for Rheumatology /ID# 142784
    Albany, New York 12206, United States
  • North Shore University Hospital /ID# 142772
    New Hyde Park, New York 11040, United States
  • Buffalo Rheumatology /ID# 142766
    Orchard Park, New York 14127, United States
  • Joint & Muscle Research Instit /ID# 142797
    Charlotte, North Carolina 28204, United States
  • DJL Clinical Research, PLLC /ID# 142769
    Charlotte, North Carolina 28210-8508, United States
  • Cape Fear Arthritis Care /ID# 148344
    Leland, North Carolina 28451, United States
  • Coastal Carolina Health Care /ID# 148351
    New Bern, North Carolina 28562, United States
  • Shanahan Rheuma & Immuno /ID# 142812
    Raleigh, North Carolina 27617, United States
  • Trinity Health Med Arts Clinic /ID# 142754
    Minot, North Dakota 58701, United States
  • Cincinnati Rheumatic Disease Study Group, Inc. /ID# 142791
    Cincinnati, Ohio 45242-4468, United States
  • STAT Research, Inc. /ID# 142821
    Vandalia, Ohio 45377-9464, United States
  • Health Research Oklahoma /ID# 142751
    Oklahoma City, Oklahoma 73103-2400, United States
  • Healthcare Research Consultant /ID# 142815
    Tulsa, Oklahoma 74135, United States
  • East Penn Rheumatology Assoc /ID# 142790
    Bethlehem, Pennsylvania 18015, United States
  • Clinical Research Ctr Reading /ID# 151714
    Wyomissing, Pennsylvania 19610, United States
  • Columbia Arthritis Center /ID# 153728
    Columbia, South Carolina 29204, United States
  • West Tennessee Research Inst /ID# 142739
    Jackson, Tennessee 38305, United States
  • Arthritis Associates, PLLC /ID# 142774
    Kingsport, Tennessee 37660, United States
  • Arthritis Associates, PLLC /ID# 155462
    Kingsport, Tennessee 37660, United States
  • Dr. Ramesh Gupta /ID# 142767
    Memphis, Tennessee 38119, United States
  • Tekton Research, Inc. /ID# 142805
    Austin, Texas 78745, United States
  • Diagnostic Group Integrated He /ID# 148340
    Beaumont, Texas 77701, United States
  • Arth and Osteo Clin Brazo Valley /ID# 148343
    College Station, Texas 77845, United States
  • Arthritis Care and Diagnostic /ID# 151344
    Dallas, Texas 75231, United States
  • Metroplex Clinical Research /ID# 142758
    Dallas, Texas 75231, United States
  • Rheumatic Disease Clin Res Ctr /ID# 150914
    Houston, Texas 77004, United States
  • Baylor College of Medicine /ID# 142753
    Houston, Texas 77030-3411, United States
  • Rheumatology Clinic of Houston /ID# 150915
    Houston, Texas 77065, United States
  • Houston Institute for Clin Res /ID# 142768
    Houston, Texas 77074, United States
  • Pioneer Research Solutions, Inc. /ID# 151346
    Houston, Texas 77098-5294, United States
  • Arthritis & Osteoporosis Assoc /ID# 147567
    Lubbock, Texas 79424, United States
  • P&I Clinical Research /ID# 151345
    Lufkin, Texas 75904-3132, United States
  • SW Rheumatology Res. LLC /ID# 142813
    Mesquite, Texas 75150, United States
  • Trinity Universal Research Association /ID# 149278
    Plano, Texas 75024-5283, United States
  • Arthritis & Osteo Ctr of S. TX /ID# 142773
    San Antonio, Texas 78232, United States
  • Arthritis Clinic of Central TX /ID# 148346
    San Marcos, Texas 78666, United States
  • DM Clinical Research /ID# 151007
    Tomball, Texas 77375, United States
  • Arthritis & Osteoporosis Clinic /ID# 142760
    Waco, Texas 76710, United States
  • Western Washington Arthritis C /ID# 142776
    Bothell, Washington 98021, United States
  • Arthritis Northwest, PLLC /ID# 150924
    Spokane, Washington 99204, United States

Showing the first 100 of 188 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, Zhou Y, Mohamed MF, Meerwein S, Pangan AL. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018 Jun 23;391(10139):2513-2524. doi: 10.1016/S0140-6736(18)31116-4. Epub 2018 Jun 18. PubMed 29908670 ↗
  • Bergman M, Buch MH, Tanaka Y, Citera G, Bahlas S, Wong E, Song Y, Zueger P, Ali M, Strand V. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials. Rheumatol Ther. 2022 Dec;9(6):1517-1529. doi: 10.1007/s40744-022-00483-4. Epub 2022 Sep 20. PubMed 36125701 ↗
  • Yamaoka K, Tanaka Y, Kameda H, Khan N, Sasaki N, Harigai M, Song Y, Zhang Y, Takeuchi T. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Saf. 2021 Jun;44(6):711-722. doi: 10.1007/s40264-021-01067-x. Epub 2021 May 27. PubMed 34041702 ↗
  • Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L, Zhang Y, Khan N, Hendrickson B, Enejosa JV, Burmester GR. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021 Mar;80(3):304-311. doi: 10.1136/annrheumdis-2020-218510. Epub 2020 Oct 28. Erratum In: Ann Rheum Dis. 2021 May;80(5):e83. doi: 10.1136/annrheumdis-2020-218510corr1. PubMed 33115760 ↗
  • Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, Song Y, Pope J. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. Arthritis Res Ther. 2019 Dec 2;21(1):263. doi: 10.1186/s13075-019-2059-8. PubMed 31791386 ↗
  • Nader A, Mohamed MF, Winzenborg I, Doelger E, Noertersheuser P, Pangan AL, Othman AA. Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis. Clin Pharmacol Ther. 2020 Apr;107(4):994-1003. doi: 10.1002/cpt.1671. Epub 2019 Nov 30. PubMed 31610021 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: For details on when studies are available for sharing, please refer to the link below.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Apr 2017, 12 months.

Results were first posted in Oct 2019, 2 years 6 months after primary completion. A results delay was requested in Feb 2018.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 12 months is below that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2016
First posted
Mar 11, 2016
StartActual
Mar 15, 2016
Primary completionActual
Apr 3, 2017
CompletionActual
Feb 8, 2022
Results delay requested
Feb 5, 2018
Results first posted
Oct 7, 2019
Last update
Feb 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02706847
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 11, 2016
Start date
Mar 15, 2016
Primary completion
Apr 3, 2017
Completion
Feb 8, 2022
Results posted
Oct 7, 2019
Last update
Feb 8, 2023

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion